{"protocolSection": {"identificationModule": {"nctId": "NCT01581710", "orgStudyIdInfo": {"id": "CHA-121"}, "organization": {"fullName": "CHA University", "class": "OTHER"}, "briefTitle": "Response of FeNO, Small Airway Dysfunction and Lung Heterogeneity to 2-week Montelukast Treatment in Asthmatic Children.", "officialTitle": "A Double-blind, Randomized, Cross-over Design Study to Compare the Lung Function Measure of Montelukast Versus Placebo in Children With Mild Persistent Asthma"}, "statusModule": {"statusVerifiedDate": "2018-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-05"}, "primaryCompletionDateStruct": {"date": "2015-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-04-13", "studyFirstSubmitQcDate": "2012-04-19", "studyFirstPostDateStruct": {"date": "2012-04-20", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-07-31", "resultsFirstSubmitQcDate": "2018-03-14", "resultsFirstPostDateStruct": {"date": "2018-04-12", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-03-14", "lastUpdatePostDateStruct": {"date": "2018-04-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Man Yong Han", "investigatorTitle": "Professor", "investigatorAffiliation": "CHA University"}, "leadSponsor": {"name": "CHA University", "class": "OTHER"}, "collaborators": [{"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study aims to identify markers to prove rapid improvement of lung function, airway inflammation and bronchodilator response after 2-week LTRA administration.", "detailedDescription": "This study is a randomized, double-blind, placebo-controlled, cross-over study with a washout period of at least one week between each study period.\n\nAfter an initial screening visit, subjects entered a screening period of one to two weeks to ensure clinical stability without medication, which means absence of daily asthma symptoms. Eligible subjects were randomized into either the treatment portion of the trial, in which subjects received montelukast (4 mg or 5 mg) or matching placebo monotherapy in a randomized manner. During each treatment period, which lasted 2 weeks, the study medication was administered between 8:00 and 9:00 A.M. Short acting bronchodilator (for severe symptoms) was permitted during the study period but was withheld 24 hours prior to bronchodilator challenge test.\n\nInclusion criteria will be mild persistent asthma children old enough to cooperate on performing pulmonary function testing, children with no respiratory symptoms 4 weeks prior to the beginning of the study. Exclusion criteria will be the following: respiratory symptoms including cough, wheezing, dyspnea, or shortness of breath, presence of acute or chronic upper respiratory infections, anatomical nasal disorders (ex, nasal polyps, septum deviation, etc.), previous or current specific immunotherapy, use of systemic corticosteroids, or admission or visit of the emergency department during the previous 4 weeks."}, "conditionsModule": {"conditions": ["Mild Persistent Asthma"], "keywords": ["Leukotriene Antagonists", "Bronchodilator response"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "PREVENTION", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 32, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "montelukast to placebo", "type": "ACTIVE_COMPARATOR", "description": "14 days", "interventionNames": ["Drug: Montelukast to placebo"]}, {"label": "Washout", "type": "NO_INTERVENTION", "description": "14 days"}, {"label": "Placebo to montelukast", "type": "ACTIVE_COMPARATOR", "description": "14 days", "interventionNames": ["Drug: Placebo to montelukast"]}], "interventions": [{"type": "DRUG", "name": "Montelukast to placebo", "description": "Subjects will receive montelukast (4 mg or 5 mg) Each treatment period consists of 2 weeks", "armGroupLabels": ["montelukast to placebo"], "otherNames": ["SINGULAIR 4mg or 5mg"]}, {"type": "DRUG", "name": "Placebo to montelukast", "description": "Subjects will receive matching placebo. Each treatment period consists of 2 weeks", "armGroupLabels": ["Placebo to montelukast"], "otherNames": ["SINGULAIR 4mg or 5mg matching placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Baseline Lung Function of Rrs 5 With IOS Before the Bronchodilator (Pre-Rrs5)", "description": "Pre Rrs 5: Resistance at 5Hz before the administration of bronchodilator", "timeFrame": "up to 2 weeks"}, {"measure": "Baseline Lung Function of Xrs5 With IOS Before the Bronchodilator (Pre-Xrs 5)", "description": "Pre Xrs 5: Reactance at 5Hz before the administration of bronchodilator", "timeFrame": "up to 2 weeks"}, {"measure": "Baseline Lung Function of Rrs10 With IOS Before the Bronchodilator", "description": "Pre Rrs10: Resistance at 10Hz before the administration of bronchodilator", "timeFrame": "up to 2 weeks"}, {"measure": "Baseline Lung Function of Xrs10 With IOS Before the Bronchodilator (Pre-Xrs10)", "description": "Pre Xrs 10: Reactance at 10Hz before the administration of bronchodilator", "timeFrame": "up to 2 weeks"}, {"measure": "Baseline Lung Function of FEV1 Before the Bronchodilator", "description": "baseline lung function in forced expiratory volume in 1 second before the administration of bronchodilator", "timeFrame": "up to 2 weeks"}, {"measure": "Baseline Lung Function of FEV1/FVC Before the Bronchodilator", "description": "baseline lung function in forced expiratory volume in 1 second/forced vital capacity before the administration of bronchodilator", "timeFrame": "up to 2 weeks"}, {"measure": "Baseline Lung Function in MMEF", "description": "Baseline lung function in maximal mid-expiratory flow before the administration of bronchodilator", "timeFrame": "up to 2 weeks"}], "secondaryOutcomes": [{"measure": "Relative Change (%) of FEV1 After the Bronchodilator", "description": "Relative change in percentage of FEV1 after the bronchodilator, 2weeks after placebo and montelukast administration Relative change (%) in FEV1 = (((FEV1 post-bronchodilator)-(FEV1 pre-bronchodilator))/baseline FEV1) x 100", "timeFrame": "up to 2 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* children diagnosed with mild persistent asthma patients based on the GINA guidelines\n* children old enough to cooperate in performing pulmonary function testing\n* legal guardians who sufficiently listen to the purpose and voluntarily agree with the participation to sign a written consent approved by IRB\n* children with no respiratory symptoms 4 weeks prior to the beginning of the study\n* children without chronic respiratory symptoms.\n\nExclusion Criteria:\n\n* presence of acute or chronic upper respiratory infections, anatomical nasal disorders (ex, nasal polyps, septum deviation, etc.), previous or current specific immunotherapy.\n* use of systemic corticosteroids in past 4 weeks.\n* admission or visit of the emergency department in past 4 weeks.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "3 Years", "maximumAge": "12 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Man Yong Han", "affiliation": "specify Unaffiliated", "role": "PRINCIPAL_INVESTIGATOR"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Montelukast to Placebo", "description": "Montelukast to placebo: Subjects will receive montelukast (4 mg or 5 mg) Each treatment period consists of 2 weeks"}, {"id": "FG001", "title": "Placebo to Montelukast", "description": "Placebo to montelukast: Subjects will receive matching placebo. Each treatment period consists of 2 weeks"}], "periods": [{"title": "First Intervention (14days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Washout Period (14days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Second Intervention (14days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Measure Analysis Population Description: two participants did not complete the second set test due to symptom aggravation", "groups": [{"id": "BG000", "title": "Subjects", "description": "All subjects"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "32"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6.41", "spread": "0.88"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "14"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "18"}]}]}]}, {"title": "Lung function (Forced Expiratory Volume 1, predicted %)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "%", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "92.9", "spread": "4.4"}]}]}]}, {"title": "Lung function (Forced Expiratory Volume 1/Forced Vital Capacity, predicted %)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "%", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "86.1", "spread": "2.7"}]}]}]}, {"title": "oscillometric lung function (Resistance at 5Hz, z-score)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "z-score", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.36", "spread": "0.25"}]}]}]}, {"title": "oscillometric lung fuction(Reactance at 5Hz, z-score)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "z-score", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "-1.14", "spread": "0.55"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Baseline Lung Function of Rrs 5 With IOS Before the Bronchodilator (Pre-Rrs5)", "description": "Pre Rrs 5: Resistance at 5Hz before the administration of bronchodilator", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kPa/L/s", "timeFrame": "up to 2 weeks", "groups": [{"id": "OG000", "title": "Baseline Lung Function", "description": "Before placebo or montelukast administration"}, {"id": "OG001", "title": "2 Weeks After Placebo Administration", "description": "Subjects will receive placebo. Each treatment period consists of 2 weeks"}, {"id": "OG002", "title": "2 Weeks After Montelukast Administration", "description": "Subjects will receive montelukast (4mg or 5mg) Each treatment period consists of 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.73", "spread": "0.15"}, {"groupId": "OG001", "value": "0.74", "spread": "0.20"}, {"groupId": "OG002", "value": "0.73", "spread": "0.15"}]}]}]}, {"type": "PRIMARY", "title": "Baseline Lung Function of Xrs5 With IOS Before the Bronchodilator (Pre-Xrs 5)", "description": "Pre Xrs 5: Reactance at 5Hz before the administration of bronchodilator", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kPa/L/s", "timeFrame": "up to 2 weeks", "groups": [{"id": "OG000", "title": "Baseline Lung Function", "description": "Before placebo or montelukast administration"}, {"id": "OG001", "title": "2 Weeks After Placebo Administration", "description": "Subjects will receive placebo. Each treatment period consists of 2 weeks"}, {"id": "OG002", "title": "2 Weeks After Montelukast Administration", "description": "Subjects will receive montelukast (4mg or 5mg) Each treatment period consists of 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.34", "spread": "0.11"}, {"groupId": "OG001", "value": "-0.36", "spread": "0.15"}, {"groupId": "OG002", "value": "-0.34", "spread": "0.10"}]}]}]}, {"type": "PRIMARY", "title": "Baseline Lung Function of Rrs10 With IOS Before the Bronchodilator", "description": "Pre Rrs10: Resistance at 10Hz before the administration of bronchodilator", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kPa/L/s", "timeFrame": "up to 2 weeks", "groups": [{"id": "OG000", "title": "Baseline Lung Function", "description": "Before placebo or montelukast administration"}, {"id": "OG001", "title": "2 Weeks After Placebo Administration", "description": "Subjects will receive placebo. Each treatment period consists of 2 weeks"}, {"id": "OG002", "title": "2 Weeks After Montelukast Administration", "description": "Subjects will receive montelukast (4mg or 5mg) Each treatment period consists of 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.57", "spread": "0.11"}, {"groupId": "OG001", "value": "0.55", "spread": "0.15"}, {"groupId": "OG002", "value": "0.55", "spread": "0.12"}]}]}]}, {"type": "PRIMARY", "title": "Baseline Lung Function of Xrs10 With IOS Before the Bronchodilator (Pre-Xrs10)", "description": "Pre Xrs 10: Reactance at 10Hz before the administration of bronchodilator", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kPa/L/s", "timeFrame": "up to 2 weeks", "groups": [{"id": "OG000", "title": "Baseline Lung Function", "description": "Before placebo or montelukast administration"}, {"id": "OG001", "title": "2 Weeks After Placebo Administration", "description": "Subjects will receive placebo. Each treatment period consists of 2 weeks"}, {"id": "OG002", "title": "2 Weeks After Montelukast Administration", "description": "Subjects will receive montelukast (4mg or 5mg) Each treatment period consists of 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.15", "spread": "0.22"}, {"groupId": "OG001", "value": "-0.20", "spread": "0.10"}, {"groupId": "OG002", "value": "-0.19", "spread": "0.07"}]}]}]}, {"type": "PRIMARY", "title": "Baseline Lung Function of FEV1 Before the Bronchodilator", "description": "baseline lung function in forced expiratory volume in 1 second before the administration of bronchodilator", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/s", "timeFrame": "up to 2 weeks", "groups": [{"id": "OG000", "title": "Baseline Lung Function", "description": "Before placebo or montelukast administration"}, {"id": "OG001", "title": "2 Weeks After Placebo Administration", "description": "Subjects will receive placebo. Each treatment period consists of 2 weeks"}, {"id": "OG002", "title": "2 Weeks After Montelukast Administration", "description": "Subjects will receive montelukast (4mg or 5mg) Each treatment period consists of 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.28", "spread": "0.41"}, {"groupId": "OG001", "value": "1.25", "spread": "0.47"}, {"groupId": "OG002", "value": "1.28", "spread": "0.46"}]}]}]}, {"type": "PRIMARY", "title": "Baseline Lung Function of FEV1/FVC Before the Bronchodilator", "description": "baseline lung function in forced expiratory volume in 1 second/forced vital capacity before the administration of bronchodilator", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "none (ratio)", "timeFrame": "up to 2 weeks", "groups": [{"id": "OG000", "title": "Baseline Lung Function", "description": "Before placebo or montelukast administration"}, {"id": "OG001", "title": "2 Weeks After Placebo Administration", "description": "Subjects will receive placebo. Each treatment period consists of 2 weeks"}, {"id": "OG002", "title": "2 Weeks After Montelukast Administration", "description": "Subjects will receive montelukast (4mg or 5mg) Each treatment period consists of 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "83.55", "spread": "16.33"}, {"groupId": "OG001", "value": "83.04", "spread": "1.22"}, {"groupId": "OG002", "value": "85.93", "spread": "8.06"}]}]}]}, {"type": "PRIMARY", "title": "Baseline Lung Function in MMEF", "description": "Baseline lung function in maximal mid-expiratory flow before the administration of bronchodilator", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/s", "timeFrame": "up to 2 weeks", "groups": [{"id": "OG000", "title": "Baseline Lung Function", "description": "Before placebo or montelukast administration"}, {"id": "OG001", "title": "2 Weeks After Placebo Administration", "description": "Subjects will receive placebo. Each treatment period consists of 2 weeks"}, {"id": "OG002", "title": "2 Weeks After Montelukast Administration", "description": "Subjects will receive montelukast (4mg or 5mg) Each treatment period consists of 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.40", "spread": "0.54"}, {"groupId": "OG001", "value": "1.38", "spread": "0.59"}, {"groupId": "OG002", "value": "1.46", "spread": "0.50"}]}]}]}, {"type": "SECONDARY", "title": "Relative Change (%) of FEV1 After the Bronchodilator", "description": "Relative change in percentage of FEV1 after the bronchodilator, 2weeks after placebo and montelukast administration Relative change (%) in FEV1 = (((FEV1 post-bronchodilator)-(FEV1 pre-bronchodilator))/baseline FEV1) x 100", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "% (relative change)", "timeFrame": "up to 2 weeks", "groups": [{"id": "OG000", "title": "2 Weeks After Placebo Administration", "description": "Subjects will receive placebo. Each treatment period consists of 2 weeks"}, {"id": "OG001", "title": "2 Weeks After Montelukast Administration", "description": "Subjects will receive montelukast (4mg or 5mg) Each treatment period consists of 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.68", "spread": "13.31"}, {"groupId": "OG001", "value": "5.65", "spread": "10.34"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Baseline Lung Function", "description": "Before placebo or montelukast administration", "seriousNumAffected": 0, "seriousNumAtRisk": 32, "otherNumAffected": 0, "otherNumAtRisk": 32}, {"id": "EG001", "title": "2 Weeks After Placebo Administration", "description": "Subjects will receive placebo. Each treatment period consists of 2 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 30, "otherNumAffected": 7, "otherNumAtRisk": 30}, {"id": "EG002", "title": "2 Weeks After Montelukast Administration", "description": "Subjects will receive montelukast (4mg or 5mg) Each treatment period consists of 2 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 32, "otherNumAffected": 1, "otherNumAtRisk": 32}], "otherEvents": [{"term": "asthma exacerbation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 32}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. HAN, MAN YONG", "organization": "CHA UNIVERSITY", "email": "drmesh@gmail.com", "phone": "82-31-780-6262"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M274108", "name": "Montelukast", "asFound": "Means", "relevance": "HIGH"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}